(MOLN)
NMS – Real Time Price. Currency in USD
4.05
-0.25 (-5.73%)
At close: Mar 27, 2026, 4:00 PM EDT
4.18
+0.13 (3.15%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
4.05
-0.25 (-5.73%)
At close: Mar 27, 2026, 4:00 PM EDT
4.18
+0.13 (3.15%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Name | Position |
|---|---|
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board |
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director |
| Dr. Philippe Legenne M.B.A., M.D. | Chief Medical Officer & Member of the Management Board |
| Mr. Alexander Zurcher | COO & Member of Management Board |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology |
| Mr. Martin Steegmaier Ph.D. | Chief Scientific Officer & Member of the Management Board |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development |
| Mr. Robert Hendriks | Senior VP of Finance |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | 6-K | f6k_031326.htm |
| 2026-03-12 | 6-K | molecularpartners-form6xk2.htm |
| 2026-02-02 | 6-K | f6k_020226.htm |
| 2026-01-12 | 6-K | f6k_011226.htm |
| 2025-12-08 | 6-K | f6k_120825.htm |
| 2025-11-12 | 6-K | f6k_111225.htm |
| 2025-10-30 | 6-K | q32025financialstatements.htm |
| 2025-08-25 | 6-K | moln-20250630.htm |
| 2025-06-25 | S-8 | mp-2025formsx8.htm |
| 2025-06-12 | 6-K | molecularpartners-form6xk_.htm |